Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | TYR | P14679 | 1/20 | 0.42 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 3/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5935862 | 1.00 | ALDH1A1 (0.46) | ALDH1A1MAPTNUDT1BACE1HSP90AA1 | |
| SCHEMBL19892266 | 1.00 | ALDH1A1 (0.46) | ALDH1A1MAPTNUDT1BACE1HSP90AA1 | |
| SCHEMBL29427940 | 1.00 | ALDH1A1 (0.46) | ALDH1A1MAPTNUDT1BACE1HSP90AA1 | |
| SCHEMBL5935854 | 1.00 | ALDH1A1 (0.46) | ALDH1A1MAPTNUDT1BACE1HSP90AA1 | |
| SCHEMBL30394481 | 1.00 | ALDH1A1 (0.46) | ALDH1A1MAPTNUDT1BACE1HSP90AA1 | |
| SCHEMBL31545836 | 1.00 | ALDH1A1 (0.46) | ALDH1A1MAPTNUDT1BACE1HSP90AA1 | |
| SCHEMBL3162433 | 0.98 | ALDH1A1 (0.43) | ALDH1A1MAPTNUDT1BACE1HSP90AA1 | |
| SCHEMBL29871375 | 0.98 | ALDH1A1 (0.43) | ALDH1A1MAPTNUDT1BACE1HSP90AA1 | |
| Water SCHEMBL4974800 | 0.96 | ALDH1A1 (0.42) | ALDH1A1MAPTNUDT1BACE1HSP90AA1 | |
| SCHEMBL19249421 | 0.89 | TYR (0.48) | ALDH1A1MAPTTYRESR2CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 695 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144739-A1 | A SKIN BRIGHTENING COMPOSITION | CONOPCO, INC., D/B/A UNILEVER (US) | 2026-05-28 | — | — | US | claimed |
| EP-4615399-B1 | A SKIN BRIGHTENING COMPOSITION | UNILEVER IP HOLDINGS B V (NL) | 2026-05-20 | — | — | EP | claimed |
| US-12622861-B2 | Stable wash composition | CONOPCO, INC. (US) | 2026-05-12 | — | — | US | claimed |
| WO-2026041386-A1 | ANHYDROUS COMPOSITION COMPRISING MONOESTERS AND MAINLY PETROLATUM | UNILEVER IP HOLDINGS B.V. (NL) | 2026-02-26 | — | — | WO | claimed |
| EP-3675806-B1 | PERSONAL CARE COMPOSITION | UNILEVER GLOBAL IP LTD (GB) | 2026-01-21 | — | — | EP | claimed |
| EP-3886791-B1 | CLAY MASK COMPOSITION AND METHOD FOR USING THE SAME | UNILEVER GLOBAL IP LTD (GB) | 2025-11-12 | — | — | EP | claimed |
| EP-4493146-B1 | A SKIN BRIGHTENING COMPOSITION | UNILEVER IP HOLDINGS B V (NL) | 2025-11-05 | — | — | EP | claimed |
| EP-4637692-A1 | COLOR STABILIZATION OF FORMULAE WITH AN INDOLE | Unilever IP Holdings B.V. (NL) | 2025-10-29 | — | — | EP | claimed |
| EP-4637690-A1 | OIL-CONTINUOUS COSMETIC COMPOSITION | Unilever IP Holdings B.V. (NL) | 2025-10-29 | — | — | EP | claimed |
| EP-4358928-B1 | COSMETIC COMPOSITION WITH ENHANCED COLOR STABILITY | UNILEVER IP HOLDINGS B V (NL) | 2025-10-22 | — | — | EP | claimed |
| US-20030185773-A1 | Stabilization of sunscreens in cosmetic compositions | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2003-10-02 | — | — | US | claimed |
| US-20030185867-A1 | Stabilization of terpenoids in cosmetic compositions | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2003-10-02 | — | — | US | claimed |
| US-20030180234-A1 | Stabilization of resorcinol derivatives in cosmetic compositions | UNILEVER HOME & PERSONAL CARE USA, | 2003-09-25 | — | — | US | claimed |
| EP-0904774-B1 | Resorcinol derivatives | PFIZER PROD INC (US) | 2003-03-26 | — | — | EP | claimed |
| CN-1270509-A | Resorcinol derivatives | PFIZER PROD INC (US) | 2000-10-18 | — | — | CN | claimed |
| US-6132740-A | SKIN LIGHTENING AGENTS; TYROSINASE INHIBITORS; ANTIINFLAMMATORY AGENTS; 4-CYCLOPENTYL- OR CYCLOPENTENYLRESORCINOLS | PFIZER INC. (US) | 2000-10-17 | — | — | US | claimed |
| WO-1999015148-A1 | RESORCINOL DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1999-04-01 | — | — | WO | claimed |
| EP-0904774-A1 | Resorcinol derivatives | Pfizer Products Inc. (US) | 1999-03-31 | — | — | EP | claimed |
| US-4886549-A | Vat dye and sulfur dye compositions | CIBA-GEIEGY CORPORATION (US) | 1989-12-12 | — | — | US | claimed |
| US-4321257-A | Potentiated medicaments | JOHNSON & JOHNSON (US) | 1982-03-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030185773-A1 | Stabilization of sunscreens in cosmetic compositions | RCOR1, CBR1, NQO1 | ALDH1A1 350/4885MAPT 1989/4885NUDT1 3266/4885 |
| US-12622861-B2 | Stable wash composition | ALG1, IL4, CUTA | ALDH1A1 2492/4885MAPT 1233/4885NUDT1 4737/4885 |
| US-20030180234-A1 | Stabilization of resorcinol derivatives in cosmetic compositions | RCOR1, RCOR3, MCOLN2 | ALDH1A1 906/4885MAPT 2540/4885NUDT1 3690/4885 |
| US-20260144739-A1 | A SKIN BRIGHTENING COMPOSITION | CUTA, MYB, RBP4 | ALDH1A1 1489/4885MAPT 2083/4885NUDT1 1119/4885 |
| US-20030185867-A1 | Stabilization of terpenoids in cosmetic compositions | SQLE, CYP51A1, RBP4 | ALDH1A1 377/4885MAPT 2452/4885NUDT1 2281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.